Doxorubicin Hydrochloride Injectable, Liposomal
Product Images NDC 70710-1530

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 70710-1530). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 01)

Chemical structure of doxorubicin hydrochloride, showing its complex multi-ring molecular arrangement with functional groups including hydroxyl, carbonyl, and amino groups, and the hydrochloride component.*

FDA Label Image

Image (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 02)

Chemical structure of doxorubicin hydrochloride illustrating a polyethylene glycol (PEG) moiety with approximately 45 repeating units, connected to a phosphatidylcholine lipid component. The diagram represents the liposomal formulation structure relevant to the injectable drug.*

FDA Label Image

Image (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 03)

Chemical structure diagram depicting a phospholipid molecule, showing the glycerol backbone, phosphate group, and two fatty acid chains with variable lengths (m, n = 14 or 16). This structure is consistent with a lipid component, relevant to the liposomal formulation of doxorubicin hydrochloride injectable.*

FDA Label Image

Image (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 04)

An illustrative diagram showing the structure of a liposomal nanoparticle for doxorubicin hydrochloride. It labels the MPEG-DSPE coating on the outer surface, the liposomal bilayer beneath it, and the aqueous core inside containing entrapped doxorubicin HCl.*

FDA Label Image

10 mL Container Label (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 05)

Label for DOXOrubicin Hydrochloride Liposome Injection, with dosage strength 20 mg/10 mL (2 mg/mL) in a 10 mL single-dose vial. The injectable liposomal formulation is for intravenous infusion only. The label includes storage instructions (refrigerate at 2° to 8°C, do not freeze), dilution requirements, and warnings not to substitute for doxorubicin HCl. Manufactured by Cadila Healthcare Limited, India, and distributed by Zydus Pharmaceuticals (USA) Inc.*

FDA Label Image

10 mL Carton Label (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 06)

Packaging label for DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) injectable liposomal solution for intravenous use. The label shows the product name, strength, dosage form, manufacturer Zydus Pharmaceuticals USA Inc., storage instructions, and caution that it is a liposomal formulation for intravenous infusion only and must be diluted before use.*

FDA Label Image

25 mL Container Label (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 07)

Label for DOXOrubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL), an injectable liposomal formulation. The label includes storage instructions (refrigerate at 2° to 8°C, do not freeze), a warning that it must be diluted and is for intravenous infusion only, and notes it is a cytotoxic agent. Manufactured by Cadila Healthcare Limited, India, and distributed by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

25 mL Carton Label (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 08)

Packaging label for Doxorubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) injectable liposomal formulation for intravenous use. The label indicates this is a cytotoxic agent that must be diluted and is for single-dose vial use. It is manufactured by Zydus Pharmaceuticals USA Inc. Storage instructions are to refrigerate at 2°C to 8°C (36°F to 46°F) and not to freeze.*

FDA Label Image

Image (B3a11bdd 2b24 4d5a 9c35 0df1ee8807c3 144 2)

A Kaplan-Meier survival curve graph showing the percent of subjects progression-free over time (months) comparing two treatment groups: Doxorubicin plus Bortezomib versus Bortezomib alone. The graph includes p-value, hazard ratio with confidence interval, and a table of subjects at risk at various time points. Censoring events are marked.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.